Jinhua Yan1, Guohe Wu1, Jianlan Chen1, Lifang Xiong1, Guoan Chen2,1, Ping Li1,1. 1. Department of Hematology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, China. 2. Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Abstract
BACKGROUND: Circulating microRNAs (miRNAs) play an essential role in the development and progression of acute myeloid leukemia (AML). However, the clinical value of serum miR-217 in AML remained poorly known. OBJECTIVE: This study aimed to explore the clinical significance of serum miR-217 in AML. METHODS: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to detect miR-217 levels in the blood samples obtained from 89 AML patients and 60 healthy controls. RESULTS: The results showed that miR-217 expression was significantly decreased in AML patients compared to controls. Likewise, serum miR-217 levels were greatly downregulated in the AML patients with poor risk cytogenetic. ROC analysis demonstrated that serum miR-217 could effectively differentiate AML patients from normal controls. Also, miR-217 expression was markedly increased in patients achieving complete remission after their treatment. In addition, low miR-217 expression was associated with aggressive clinical features. Moreover, Kaplan-Meier analysis showed that AML patients with low miR-217 expression tended to have shorter overall survival and disease free survival. In the multivariate analysis stratified for prognostic parameters, miR-217 was proved to be an independent prognostic indicator. CONCLUSIONS: Collectively, miR-217 was identified as an independent marker for the diagnosis and prognosis of AML.
BACKGROUND: Circulating microRNAs (miRNAs) play an essential role in the development and progression of acute myeloid leukemia (AML). However, the clinical value of serum miR-217 in AML remained poorly known. OBJECTIVE: This study aimed to explore the clinical significance of serum miR-217 in AML. METHODS: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to detect miR-217 levels in the blood samples obtained from 89 AMLpatients and 60 healthy controls. RESULTS: The results showed that miR-217 expression was significantly decreased in AMLpatients compared to controls. Likewise, serum miR-217 levels were greatly downregulated in the AMLpatients with poor risk cytogenetic. ROC analysis demonstrated that serum miR-217 could effectively differentiate AMLpatients from normal controls. Also, miR-217 expression was markedly increased in patients achieving complete remission after their treatment. In addition, low miR-217 expression was associated with aggressive clinical features. Moreover, Kaplan-Meier analysis showed that AMLpatients with low miR-217 expression tended to have shorter overall survival and disease free survival. In the multivariate analysis stratified for prognostic parameters, miR-217 was proved to be an independent prognostic indicator. CONCLUSIONS: Collectively, miR-217 was identified as an independent marker for the diagnosis and prognosis of AML.